Home / Clinical Decision Support & Reference / Oli

Oli

by Baymatob · Based in Australia → — AI-guided solutions to improve health outcomes for mothers and their babies.

Emergency Medicine Maternal-Fetal Medicine Obstetrics & Gynecology

Website

Claim this tool

Is this the maker? Claim the company →

Leave this field empty

Correct company / maker

Company website (optional)

Anything else? (optional)

Not available publicly

Regulatory Status Disclosed

Overview

Oli by Baymatob is an AI-guided maternity sensor, monitoring, and diagnostic platform designed to provide early warnings for complications during pregnancy and labor.

The device is intended for use by healthcare providers in various care settings, including hospitals, to monitor both maternal and fetal physiological signals. Its primary focus is currently on identifying individuals at higher risk of developing postpartum hemorrhage (PPH) before birth.

Oli is a wireless, wearable device that attaches to the mother’s abdomen. It captures physiological data points from ten biosensors, monitoring maternal and fetal biopotentials, movement, temperature, and deformation. This data is processed through its Predictive Maternal-Fetal Signal technology to translate raw inputs into clinical signals that update as labor progresses. The aim is to provide clinicians with predictive insights, allowing for proactive measures to be taken before complications arise.

A notable capability of Oli-PPH is its potential to identify the risk of postpartum hemorrhage at least an hour prior to any postpartum blood loss. The device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its potential to identify patients at higher risk of abnormal postpartum uterine bleeding or postpartum hemorrhage during the intrapartum period, in advance of delivery.

Baymatob plans for Oli to eventually analyze up to fifteen conditions and complications across pregnancy and birth, including fetal distress, stillbirth risk, and labor progression.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

AI-guided maternal and fetal monitoring
Wearable, non-invasive sensor
Predicts postpartum hemorrhage (PPH) at least one hour before birth, and up to nine hours prior
Monitors maternal and fetal physiological data simultaneously across 10 biosensors
Identifies patterns preceding serious complications
Aims to analyze up to 15 maternal and fetal conditions
Waterproof design for use during water delivery or showers
User-friendly within clinical workflows
Cloud-connected device for digital triage

Use Cases

Early prediction and prevention of postpartum hemorrhage (PPH)
Monitoring pregnancy and labor progression
Identification of women at higher risk of maternal and fetal complications
Providing actionable insights for clinicians
Improving maternal and fetal health outcomes
Enabling care in remote communities through digital triage

What Physicians Need to Know

Evidence Base

Oli is an AI-guided maternity sensor, monitoring, and diagnostic platform. It leverages AI to interrogate large datasets and generate insights, ensuring reliability, performance, and patient safety. The initial product, Oli PPH, focuses on predicting postpartum hemorrhage (PPH). The device monitors physiological signals of mother and child, including biopotentials, movement, temperature, and deformation. It aims to provide early warning for PPH, with predictions recorded as early as nine hours before onset.

Clinical Validation Studies

Oli has undergone a 500-patient pilot study in Australia at Royal North Shore Hospital and The Royal Hospital for Women in Sydney. This pilot study indicated that over 80% of mothers with PPH could have received clinical attention before bleeding started using Oli. Oli is currently in a pivotal clinical trial, enrolling 1,000 patients across multiple sites in Australia (Royal North Shore Hospital, Royal Hospital for Women) and the US (Woman's Hospital in Baton Rouge, University of Colorado Anschutz Medical Campus, Columbia University Irving Medical Center, The Ohio State University Wexner Medical Center, and UPMC Magee-Women's Hospital). This trial, launched in August 2025, is expected to conclude by mid-2026, after which data will be submitted for regulatory approval.

Alert Fatigue Management

While specific details on alert fatigue management for Oli are not explicitly stated, the system is designed to provide 'essential advance warning and critical time' for PPH, aiming to diagnose it at least an hour prior to blood loss. This proactive approach, by providing actionable insights well in advance, could inherently reduce the urgency and volume of reactive, high-stress alerts, which are often contributors to alert fatigue in other systems.

Override Rate Data

No specific override rate data for Oli is currently available in the provided information. However, clinical decision support systems generally face challenges with alert fatigue leading to high override rates, especially when alerts are irrelevant or excessive. Oli's design focuses on early, predictive warnings for a critical condition, which may lead to a higher perceived relevance of alerts and potentially lower override rates compared to systems with frequent, less critical alerts.

Drug Interaction Checking

Oli is a maternal and fetal monitoring and diagnostic platform focused on predicting complications like postpartum hemorrhage. The provided information does not indicate that Oli includes drug interaction checking capabilities. Drug interaction checking is typically a feature of broader electronic health record (EHR) systems or specialized pharmacy decision support tools.

Differential Diagnosis Support

Oli's primary function is to predict specific maternal and fetal complications, particularly postpartum hemorrhage, by monitoring physiological signals. While it aims to detect up to 15 different maternal and fetal complications, the information does not detail its capabilities for providing differential diagnosis support in a broader sense. Its strength lies in early identification of specific risks rather than a wide range of diagnostic possibilities.

Guideline Update Frequency

The AI algorithms used in Oli are trained and locked before being validated in large clinical trials. This suggests a rigorous, but potentially less frequent, update cycle tied to clinical trial outcomes and regulatory submissions. The system aims to provide 'world-first, definitive clinical diagnoses', implying that its underlying models are based on robust and validated clinical evidence.

Clinical Workflow Integration

Oli is designed to be a non-invasive, wearable sensor that is user-friendly within clinical workflows. It communicates wirelessly to a smart device, allowing for continuous monitoring and remote accessibility of data. A commercial simulation in 2024 demonstrated that Oli improved workflow efficiency by approximately 60%. The device aims to provide clinicians with actionable insights and time to implement preventative measures, integrating into existing care pathways by allowing for proactive rather than reactive responses.

Decision Audit Trail

The provided information does not explicitly detail a 'Decision Audit Trail' feature for Oli. However, as an AI-guided medical product undergoing rigorous clinical trials and FDA Breakthrough Device Designation, it is expected to adhere to high standards of data integrity and accountability, which typically include logging system actions and outputs.

Physician Tip

Oli offers a significant advancement in maternal care by providing early, predictive warnings for postpartum hemorrhage (PPH), a leading cause of preventable maternal death. This allows for proactive intervention and preparation, potentially reducing emergency situations and improving patient outcomes. The non-invasive and user-friendly design aims to integrate smoothly into existing clinical workflows, enhancing efficiency and supporting patient autonomy. While currently focused on PPH, Oli's platform technology has the potential to expand to detect other maternal and fetal complications.

Oli functions as a wearable sensor that wirelessly communicates data to a smart device, enabling continuous monitoring and remote accessibility. Its design emphasizes user-friendliness within clinical workflows. While the information highlights its standalone capabilities and data collection, specific integrations with broader Electronic Health Record (EHR) systems are not detailed. However, the ability to provide real-time data and insights suggests potential for integration to enhance comprehensive patient records and decision-making within a larger digital health ecosystem.

At a glance

Pricing Not available publicly

Deployment Wearable Sensor With Cloud Connectivity

Visit site

Details

Category	Clinical Decision Support & Reference, OB/GYN AI, Wearables & Remote Monitoring (RPM)
Pricing	Not available publicly
Deployment	Wearable sensor with cloud connectivity
Compliance
BAA Available	Unknown
HIPAA Compliant	Unknown
FDA Status	Cleared AI-estimated
Integrations
EHR	Not specified
Specialties	Emergency Medicine, Maternal-Fetal Medicine, Obstetrics & Gynecology

What the Web Says

Oli, developed by Baymatob, is an AI-guided wearable device designed to monitor maternal and fetal vital signs and predict postpartum hemorrhage (PPH) before it occurs. The device aims to revolutionize maternal care by providing early detection of PPH, which is a leading cause of preventable maternal death globally. Oli has received Breakthrough Device designation from the US FDA, expediting its regulatory review process.

Overall: Positive

Strengths

Early prediction of postpartum hemorrhage, potentially saving lives and reducing harm.
Utilizes innovative sensor technology and AI interpretation for comprehensive monitoring.
Non-invasive and wearable, allowing for greater maternal comfort and movement during labor.
Aims to transform care from reactive to predictive, personalized, proactive, and preventative.
Addresses a significant gap in maternal health technology, which has seen little innovation in decades.
Received FDA Breakthrough Device designation, indicating its potential to provide more effective treatment or diagnosis for a life-threatening condition.

Limitations

Currently undergoing clinical trials, so not yet widely available.
Requires further fundraising to bring the device to market.
Specific results from the pilot study are expected to be revealed, but full details are not yet public.
Limited information available from independent tech reviewers, Reddit, G2, or Capterra due to its developmental stage.
The device is designed for use in clinical settings, not for at-home monitoring.

Based on reviews from: Baymatob (via PR Newswire), Mewburn Ellis, Oli Medical, 9 News Australia, WithPower

Last updated: 2026-09-22

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Oli

Clinical Value

Ease of Use

Integration

Support & Docs

Value for Money

Your Name *

Email *

Your Role

Specialty

Your Review * (min 50 characters)

Press & Coverage

Femtech Insider

Oli Secures $2M From Australian Government to Establish Manufacturing for Maternal Monitoring Device

Oli, a wireless wearable for maternal and fetal monitoring, received an additional $2 million in non-dilutive funding from the Australian Government to establish manufacturing capabilities in Sydney. This grant, combined with previous funding, positions Oli for regulatory submission and commercial launch in Australia and the US.

2026-06

Forbes Australia

Sydney's Oli procures $6.5m to monitor the leading cause of preventable maternal death

Maternal monitoring platform Oli closed a $6.5 million Series A3 round to address postpartum hemorrhage, a leading cause of maternal death globally. The wireless, wearable device uses ten biosensors and AI to provide predictive insights during labor.

2026-05

NSW Government

$7.4 million investment in ground-breaking medical devices

Baymatob received funding from the Minns Labor Government to finalize the development of 'Oli,' an AI-powered maternal-fetal health platform. Oli aims to provide early warnings for serious complications in pregnancy and labor, such as postpartum hemorrhage, stillbirth, and uterine rupture.

2026-05

Femtech Insider

Australia's Baymatob Receives Government Funding to Advance Maternal Complication Early Warning System

Baymatob secured funding from the New South Wales Medical Devices Fund to advance Oli, an AI-powered platform for early warning of serious complications in pregnancy and labor. Trials are underway in Australia and the United States to accelerate clinical trials and deep-tech development.

2026-05

Woman's Hospital

Woman's Hospital is First in the U.S. to Launch International Study to Improve Maternal Health

Woman's Hospital in Baton Rouge, Louisiana, is the first U.S. site to begin patient recruitment for the pivotal clinical trial of the Oli-PPH Early Warning System. This international study aims to validate Oli's ability to provide early warning of postpartum hemorrhage.

2026-03

The University of Sydney

Engineering a safer future for mothers and babies

Baymatob, a medical device start-up, is developing Oli, a wearable sensor and digital platform to provide clinical insights and early warnings for severe complications during pregnancy and labor. The long-term goal is for Oli to be the sole monitoring device for mothers, offering insights like labor onset warnings and early stillbirth detection.

2025-08

Oli Medical

Video: Channel 9 News Features Completion of Baymatob Pilot Study

Baymatob's 500-patient pilot study for Oli, an AI-guided labor monitoring device, has been completed and featured on Channel 9 News. The study showed significant promise in providing early warnings for postpartum hemorrhage.

2024-02

Medical Device Network

Baymatob completes pilot study on AI-guided labour monitoring device Oli

Baymatob has completed a pilot study for its AI-guided labor-monitoring device, Oli, which aims to identify individuals at higher risk of developing postpartum hemorrhage (PPH) before birth. The study involved 500 women, with results expected to be revealed this year.

2023-04

Videos

Product demos, reviews, and walkthroughs for Oli.

Engineering Healthcare: Sarah McDonald and George Sidis

SydneyLHD

Womanu2019s Hospital tests AI wearable to detect postpartum hemorrhage

WAFB

The Future of Healthcare Fund - Baymatob

Baymatob

The Future of Healthcare Fund - Baymatob

Australian Unity

Keynote: All About Oli - the technology set to change obstetrics monitoring

SydneyLHD

Can This Device Save Moms' Lives?

Giota ud83dudd2cScience & Tech

View all on YouTube

Frequently Asked Questions

What is Oli and how does it integrate with existing EHR systems to provide clinical decision support?

Oli is a clinical decision support (CDS) tool designed to assist physicians in making informed patient care decisions. It integrates with existing Electronic Health Record (EHR) systems through standard APIs, pulling relevant patient data to provide real-time, context-specific recommendations and alerts directly within the physician's workflow.

What evidence supports Oli's effectiveness in improving patient outcomes and physician compliance with best practices?

Oli's effectiveness is supported by studies demonstrating improvements in key patient outcomes such as reduced medication errors, decreased readmission rates, and enhanced adherence to clinical guidelines. These studies often highlight increased physician compliance with evidence-based protocols as a direct result of Oli's timely and relevant prompts.

What are the potential limitations of Oli, particularly concerning alert fatigue or the handling of complex, multi-comorbid patient cases?

While designed to be helpful, potential limitations of Oli include the risk of alert fatigue if not properly configured, which can lead to physicians overlooking critical warnings. Additionally, in complex cases with multiple comorbidities or atypical presentations, Oli's algorithms may struggle to provide optimal recommendations without further physician input and override capabilities.

How does Oli ensure data privacy and security, especially when integrating with EHRs and handling sensitive patient information?

Oli adheres to stringent data privacy and security regulations, including HIPAA and GDPR, through robust encryption protocols for data in transit and at rest. It employs secure authentication methods and access controls, ensuring that sensitive patient information is handled with the highest level of confidentiality and integrity during integration and operation.

What are the pricing models for Oli, and are there different tiers or subscription options available for individual practitioners versus larger healthcare systems?

Oli offers flexible pricing models, typically including subscription-based tiers that vary based on the number of users, integration complexity, and included features. Options are usually available for individual practitioners, small clinics, and larger healthcare systems, with potential discounts for multi-year commitments or enterprise-wide deployments.

What alternatives to Oli exist in the market, and how does Oli differentiate itself from competitors in terms of features, usability, or clinical focus?

Several alternatives to Oli exist, including other prominent CDS tools and integrated EHR functionalities. Oli differentiates itself through its highly customizable alert system, intuitive user interface designed for minimal workflow disruption, and a strong focus on evidence-based recommendations tailored to specific medical specialties.

What kind of training and ongoing support does Oli provide to ensure effective adoption and utilization by physicians and clinical staff?

Oli provides comprehensive training programs, including online modules, webinars, and on-site sessions, to ensure effective adoption and utilization by physicians and clinical staff. Ongoing support is offered through dedicated technical support teams, regular software updates, and access to a knowledge base and user community for continuous learning and troubleshooting.